Open AccessHepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
Author(s) -
Cristina Maria Muzîca,
C Stanciu,
Laura Huiban,
Ana-Maria Sîngeap,
Cătălin Sfarti,
Sebastian Zenovia,
Camelia Cojocariu,
Anca Trifan
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i43.6770
Subject(s) - hepatocellular carcinoma , hepatitis c virus , antiviral therapy , virology , medicine , hepacivirus , hepatitis c , hepatitis b virus , virus , cancer research , chronic hepatitis
Direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV) infection, achieving high rates (≥ 95%) of sustained virological response, with a good safety profile and high compliance rates. Consequently, it had been expected that viral clearance will reduce morbidity and mortality rates, as well as the risk of hepatocellular carcinoma (HCC). However, since 2016, concerns have been raised over an unexpected high rate of HCC occurrence and recurrence after DAA therapy, which led to an avalanche of studies with contradictory results. We aimed to review the most recent and relevant articles regarding the risk of HCC after DAA treatment and identify the associated risk factors.